Noninvasive prenatal blood group genotyping

Area of Science:

• Genetics
• Molecular Biology
• Prenatal Diagnostics

Background:

• Noninvasive fetal RHD genotyping from maternal plasma is a vital prenatal diagnostic tool.
• A key challenge is ensuring the reliability of negative results, which can be compromised by insufficient free fetal DNA (ffDNA).
• False negative results pose significant risks to fetal health and must be reliably excluded.

Purpose of the Study:

• To present a protocol for including standards in real-time PCR assays.
• To assess the presence of adequate amounts of ffDNA in maternal blood for prenatal genotyping.
• To enhance the reliability of noninvasive fetal RHD determination.

Main Methods:

• Development of a real-time PCR protocol incorporating internal standards.
• Quantification of ffDNA in maternal plasma samples.
• Validation of the protocol for prenatal RHD genotyping.

Main Results:

• The protocol enables the assessment of ffDNA quantity, distinguishing true negatives from false negatives.
• Inclusion of standards improves the reliability of noninvasive fetal RHD typing.
• The method addresses a critical pitfall in current prenatal diagnostic assays.

Conclusions:

• The presented protocol enhances the accuracy and reliability of noninvasive fetal RHD genotyping.
• This method is essential for excluding false negative results and ensuring fetal safety.
• Implementing internal standards is crucial for robust prenatal diagnosis using ffDNA.